Navigation Links
Positive Clinical Results for DG041 Lead Product Development,Highlights at deCODE R&D Event

Recent clinical studies support the development of DG041 as an effective anti-platelet that does not increase bleeding risk

REYKJAVIK, Iceland, June 25, 2007 /PRNewswire-FirstCall/ -- deCODE genetics today announced progress in the development of DG041, the company's Phase II developmental compound for the prevention of arterial thrombosis. The results of the Phase IIa and clinical pharmacology studies presented today build upon previous findings demonstrating DG041's profile as an anti-platelet compound that deCODE expects will make it possible to block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. There is a large unmet medical need for a drug with these characteristics, with applicability to the prevention of heart attack, stroke and the progression of peripheral artery disease (PAD). Drugs such as Plavix(TM) and aspirin, the current mainstays of oral anti-platelet therapy, significantly increase the risk of bleeding by broadly blocking platelet activity.

Recent advances in deCODE's therapeutic and diagnostics pipeline will be discussed at the company's annual R&D event being held today in Reykjavik. The presentations will be webcast live through the investors page of the company's website at http://www.decode.com, starting at 9am GMT/5am EDT, and will be archived on the site. Among the highlights to be discussed are:

DG041 -- Arterial thrombosis.

DG041 is a novel, first in class antagonist of the EP3 receptor for prostaglandins E2. deCODE initially identified EP3 as a target by isolating variants in the gene encoding the EP3 receptor for prostaglandins E2 (PGE2) that approximately double the risk of PAD, a common and debilitating atherosclerotic condition in which the flow of blood to the legs is progressively constricted. The mechanism through which EP3
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:5/6/2015)... Johnson & Johnson (NYSE: JNJ ) ... party to review requests made to the Janssen Pharmaceutical ... compassionate use of its investigational medicines. This new approach ... single Janssen investigational medicine and, if successful, will become ... Johnson & Johnson. In keeping with the ...
(Date:5/6/2015)... 6, 2015  Zimmer Holdings, Inc. (NYSE and SIX: ZMH), ... will be presenting at the Bank of America Merrill Lynch ... Las Vegas, Nevada on Wednesday, May ... live webcast of the presentation can be accessed via Zimmer,s ... be archived for replay following the conference. About ...
(Date:5/6/2015)... NEW YORK , May 6, 2015  The ... ("GEVA" or the "Company") by Alexion Pharmaceuticals, Inc. ("Alexion") ... action, shareholder rights law firm, for possible breaches of ... Board of Directors of GEVA for agreeing to sell ... Company announced a definitive agreement for Alexion to acquire ...
Breaking Medicine Technology:Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 2Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 3Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 4Johnson & Johnson Announces NYU School of Medicine Partnership To Evaluate Compassionate Use of Investigational Medicines 5WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2
... Neuralstem, Inc. (NYSE Amex: CUR ) announced ... trial to test its neuroregenerative small molecule drug, NSI-189, in ... the drug in healthy volunteers for safety and tolerability. Phase ... will test the safety and tolerability of NSI-189 in depressed ...
... Since its initial inception, Echosens has ... and strengthen its product range with the recent introduction ... Equipped with a new and more ergonomic tactile interface, ... latest FibroScan ® provides a reliable, accurate and ...
Cached Medicine Technology:Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 2Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial 3Echosens: Launch of the FibroScan®502 Touch 2
(Date:5/6/2015)... As the exclusive hospital of the Tampa Bay Buccaneers, Florida ... Raymond James Stadium for all the “Bucs Babies” celebrating their ... into the “Bucs Babies” program last year. , “It ... particularly those born at the Florida Hospitals here in our ... really enjoyed my time participating in the festivities, interacting with ...
(Date:5/6/2015)... 2015 On April 27, 2015, Elle ... Surgery ,” compiled quotes about cosmetic surgery from 16 ... singer Iggy Azalea, and Gwyneth Paltrow. For the most ... plastic surgery themselves; only a couple of ... expectations of youth and beauty. (see: goo.gl/wSomih) , “The ...
(Date:5/6/2015)... May 06, 2015 Chesapeake Regional ... state of Virginia to acquire Intuitive Surgical, Inc.’s ... The system upgrade includes enhanced surgical technique capabilities, ... procedures across a wide spectrum of specialties. Its ... pain and quicker recovery times. , “As the ...
(Date:5/6/2015)... PA (PRWEB) May 06, 2015 TMG ... solutions to the Medicare Advantage, Medicare Part D and ... the Continuity and Resilience Team category at the BCI ... Continuity Institute to recognize the outstanding contribution of business ... the North America Region, including the USA and Canada. ...
(Date:5/6/2015)... Boulder, CO (PRWEB) May 06, 2015 ... Boulder, Colo., specializes in yoga and Pilates classes, ... services, videos and products, starting with its new ... In the effort of becoming leaner, stronger, more ... Pilates Ring offer a fresh venue to healthy ...
Breaking Medicine News(10 mins):Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 2Health News:Florida Hospital and the Tampa Bay Buccaneers Celebrate “Bucs Babies” Who are Turning One this Month with a Party on the Pirate Ship 3Health News:Plastic Surgery: Sixteen Celebrities Offer their Opinion about Going Under the Knife 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 2Health News:Chesapeake Regional Medical Center Obtains First da Vinci® XI Robotic Surgical System in Virginia 3Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3
... twice before buying their next pair of high-heels or pumps, ... Hebrew SeniorLife in a new study of older adults and ... women wear, specifically high-heels, pumps and sandals, may cause future ... who reported hind-foot pain regularly wore these types of shoes ...
... individuals from the field of pharmaceutical research are expected to ... - 12, 2009 at the Los Angeles Convention Center in ... have the opportunity to present new research, methods and technologies ... only is the meeting the premiere international event for the ...
... ... healthcare professionals, today announced that it has acquired the assets of Medical Concepts Staffing ... , ... (PRWEB) September 28, 2009 -- Temps Inc., ( www.tempsinc.net ) a national provider of ...
... cons of cancer screen not understood, research shows, , MONDAY, ... told the pros and cons of PSA tests, two new ... they can,t predict which cancers are aggressive and which are ... leads to overtreatment, which can have immediate consequences, such as ...
... cells to ignore premature signals to stop producing important proteins. ... Journal of Experimental Medicine , the findings could lead to ... dystrophy, that are sparked by missing proteins. "When DNA ... than the end of a protein-producing signal, they act like ...
... of Common Human Disease has been chosen as one ... of Health (NIH) grant for Centers of Excellence to ... million over five years. "We,re grateful for ... how epigenetic control affects disease," says the center,s director, ...
Cached Medicine News:Health News:Institute for Aging Research study links high-heels to heel and ankle pain 2Health News:Temps Inc. Acquires Medical Concepts Staffing Business From Analysts International Corporation 2Health News:Men Not Being Told Enough About PSA Tests 2Health News:Men Not Being Told Enough About PSA Tests 3Health News:Men Not Being Told Enough About PSA Tests 4Health News:UCLA study identifies 2 chemicals that could lead to new drugs for genetic disorders 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: